The Efficacy and Safety of Oral Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Scheduled for Electrical Cardioversion.

@article{Enomoto2016TheEA,
  title={The Efficacy and Safety of Oral Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Scheduled for Electrical Cardioversion.},
  author={Yoshinari Enomoto and Naoshi Ito and Tadashi Fujino and Mahito Noro and Takanori Ikeda and Kaoru Sugi},
  journal={Internal medicine},
  year={2016},
  volume={55 15},
  pages={
          1953-8
        }
}
Objective Electrical cardioversion (EC) is associated with an increased risk of thrombotic events in patients with non-valvular atrial fibrillation (NVAF). Patients who experience AF for a period of >48 hours therefore require adequate anticoagulation therapy for at least 3 weeks before and 4 weeks after EC. While the guidelines address the management of vitamin K antagonists (VKAs), there are limited data on the use of novel oral anticoagulants (NOAC). One NOAC, rivaroxaban, has a rapid onset… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.

  • Circulation journal : official journal of the Japanese Circulation Society
  • 2012
VIEW 2 EXCERPTS

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2010
VIEW 1 EXCERPT

Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity

J Graff, N von Hentig, F Misselwitz
  • J Clin Pharmacol
  • 2007
VIEW 2 EXCERPTS